Literature DB >> 4029018

Biliary concentrations of temocillin.

G J Poston, A Greengrass, C J Moryson.   

Abstract

Temocillin is a new semisynthetic beta-lactam antibiotic with a spectrum of activity against most aerobic Gram-negative bacteria. We investigated the biliary excretion of temocillin after administration of 1g either intravenously or intramuscularly to 15 patients with normal liver and renal function who were undergoing elective cholecystectomy for gallstones. Very high concentrations of temocillin (up to 8 times the corresponding serum concentrations) were found in common bile duct bile and gallbladder bile of functioning gallbladders 1 to 2 hours after administration. However, no temocillin was detected in the bile of non-functioning gallbladders. Concentrations of temocillin were significantly higher in common bile duct bile (p less than 0.01) and gallbladder bile (p less than 0.05) following intravenous administration, and there was also a significant correlation (p less than 0.05) between common bile duct bile and corresponding serum concentrations for both routes of administration. Temocillin 1g readily achieved therapeutic concentrations in bile, and may prove a useful agent in the prophylaxis and management of Gram-negative biliary infections.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4029018     DOI: 10.2165/00003495-198500295-00029

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  9 in total

1.  Infective cholecystitis.

Authors:  M R Keighley; N G Graham
Journal:  J R Coll Surg Edinb       Date:  1973-07

2.  The significance of infection in biliary disease.

Authors:  C S Haw; A A Gunn
Journal:  J R Coll Surg Edinb       Date:  1973-07

3.  An endogenous source for wound infections based on quantitative bacteriology of the biliary tract.

Authors:  M C Robson; J N Bogart; J P Heggers
Journal:  Surgery       Date:  1970-09       Impact factor: 3.982

4.  Bacteriologic studies of biliary tract infection.

Authors:  R J Flemma; L M Flint; S Osterhout; W W Shingleton
Journal:  Ann Surg       Date:  1967-10       Impact factor: 12.969

5.  Biliary bacteremia.

Authors:  S H Chetlin; D W Elliott
Journal:  Arch Surg       Date:  1971-04

6.  Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers.

Authors:  R M Brown; R Wise; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

7.  Multivariate analysis of clinical and operative findings associated with bilary sepsis.

Authors:  M R Keighley; R Flinn; J Alexander-Williams
Journal:  Br J Surg       Date:  1976-07       Impact factor: 6.939

8.  BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.

Authors:  B Slocombe; M J Basker; P H Bentley; J P Clayton; M Cole; K R Comber; R A Dixon; R A Edmondson; D Jackson; D J Merrikin; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

9.  Temocillin (BRL 17421): in-vitro antibacterial activity and susceptibility to beta-lactamases.

Authors:  I Phillips; A King; K Shannon; C Warren
Journal:  J Antimicrob Chemother       Date:  1982-10       Impact factor: 5.790

  9 in total
  3 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Temocillin.

Authors:  Kevin Alexandre; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

2.  Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes.

Authors:  Sylvain Chawki; Aurélien Sokal; Marion Duprilot; Amandine Henry; Véronique Leflon-Guibout; Marie-Hélène Nicolas-Chanoine; Bruno Fantin; Victoire de Lastours
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-02-20       Impact factor: 3.267

3.  Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion.

Authors:  Perrin Ngougni Pokem; Xavier Wittebole; Christine Collienne; Hector Rodriguez-Villalobos; Paul M Tulkens; Laure Elens; Françoise Van Bambeke; Pierre-François Laterre
Journal:  Antibiotics (Basel)       Date:  2022-07-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.